Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Diagnostics & Research

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. The company operates through two segments, Waters and TA. The company designs, manufactures, sells, and services liquid chromatography, as well as mass spectrometry (MS) technology systems and supports products, including chromatography columns, and other consumable products. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer goods, and healthcare products, as well as for life science research; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology, which is used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.

Revenue projections:

Revenue projections for WAT
Revenue projections for WAT

Waters Corporation's revenues are expected to fall below last year's, and this forecast tends to raise concerns among investors. A revenue drop can negatively impact the company's profitability, making investors more cautious about their positions due to the risks of declining financial performance.

Financial Ratios:

currentRatio 2.019000
forwardPE 27.702948
debtToEquity 120.473000
earningsGrowth 0.194000
revenueGrowth 0.040000
grossMargins 0.597250
operatingMargins 0.286970
trailingEps 10.480000
forwardEps 12.930000

WAT's current ratio, being 2.019, demonstrates that the company has the liquidity necessary to service its short-term debt. With strong cash reserves and current assets, WAT is well-equipped to meet its immediate financial obligations without any difficulties.
WAT's Forward PE being in a reasonable range suggests the stock is fairly priced based on its earnings. The stock isn't overpriced, leaving room for growth, making it an attractive investment for those seeking opportunities for future value appreciation.
WAT's high debt-to-equity ratio signals that the company is heavily leveraged. This suggests WAT may be relying more on debt than equity to finance its operations, which could expose the company to greater financial risk in challenging economic conditions.
WAT's positive gross and operating margins highlight its profitability and operational efficiency. These strong margins demonstrate the company's ability to control costs while generating substantial revenue, contributing to a healthy financial performance.
With a forward EPS greater than its trailing EPS, WAT is expected to see higher profitability this year. The forecasted increase in earnings reflects optimism about the company's financial growth and potential for improved performance over the prior year.

Price projections:

Price projections for WAT
Price projections for WAT

WAT's price has consistently remained near the lower edge of projections, suggesting that it is not fully meeting market expectations. This could indicate a need for improved performance or strategies to boost investor confidence.

Recommendation changes over time:

Recommendations trend for WAT
Recommendations trend for WAT


A recent sell bias for WAT from analysts suggests caution for investors. However, decisions should be grounded in a diverse set of market indicators, ensuring that a wider perspective is considered before making any moves regarding the stock's performance and potential risks.